SCHEMBL3486952

SCHEMBL3486952

N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 14/20 1.00
KDM4E B2RXH2 5/20 1.00
MEN1 O00255 5/20 1.00
ALDH1A1 P00352 5/20 1.00
CYP3A4 P08684 5/20 1.00
MAPT P10636 5/20 1.00
HPGD P15428 5/20 1.00
ALOX15 P16050 5/20 1.00
ALOX12 P18054 5/20 1.00
MAPK1 P28482 5/20 1.00
RECQL P46063 5/20 1.00
BLM P54132 5/20 1.00
KMT2A Q03164 5/20 1.00
HSD17B10 Q99714 5/20 1.00
TDP1 Q9NUW8 5/20 1.00
CYP1A2 P05177 4/20 1.00
CYP2D6 P10635 3/20 1.00
CYP2C19 P33261 3/20 1.00
CYP2C9 P11712 2/20 1.00
TP53 P04637 4/20 0.94

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6055311 1.00 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL29376415 1.00 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL2533402 1.00 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL645290 0.97 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL29378814 0.97 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL645291 0.97 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL7378564 0.92 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL6213511 0.89 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL6213506 0.89 EGFR (1.00) EGFRKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL13184692 0.89 EGFR (0.80) EGFRKDM4EMEN1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482983-A4 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS YISSUM RES DEV CO (IL) 2006-07-12 EP claimed
EP-1156775-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2006-05-17 EP claimed
EP-1482983-A2 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-12-08 EP claimed
US-20040197335-A1 Non-myeloablative tolerogenic treatment with tyrphostins HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2004-10-07 US claimed
WO-2003065971-A9 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS YISSUM RES DEV CO (IL) 2003-11-20 WO claimed
WO-2003065971-A2 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2003-08-14 WO claimed
EP-1156775-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2001-11-28 EP claimed
US-6121269-A TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS GILLETTE COMPANY, THE, A DELAWARE CORPORATION 2000-09-19 US claimed
WO-2000050002-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-08-31 WO claimed
EP-2167017-A2 COSMETIC STICK BASED ON A CONGEALED OIL-IN-WATER DISPERSION/EMULSION HAVING A HYDROGEL FORMER Henkel AG & Co. KGaA (DE) 2010-03-31 EP disclosed
EP-2167018-A2 COSMETIC STICK BASED ON A CONGEALED OIL-IN-WATER DISPERSION/EMULSION Henkel AG & Co. KGaA (DE) 2010-03-31 EP disclosed
US-20100047296-A1 Low-Residue Cosmetic Or Dermatological Stick Based On An Oil-In-Water Dispersion/Emulsion III HENKEL AG & CO. KGAA (DE) 2010-02-25 US disclosed
US-20090220444-A1 Antiperspirant and Deodorant Compositions with Improved Protective Action HENKEL AG & CO. KGAA (DE) 2009-09-03 US disclosed
EP-2011476-A2 Moisture-emitting cosmetic and dermatological compounds with enhancers Henkel AG & Co. KGaA (DE) 2009-01-07 EP disclosed
WO-2003065971-A9 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS YISSUM RES DEV CO (IL) 2003-11-20 WO disclosed
WO-2003065971-A2 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2003-08-14 WO disclosed
EP-1156775-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2001-11-28 EP disclosed
US-6121269-A TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS GILLETTE COMPANY, THE, A DELAWARE CORPORATION 2000-09-19 US disclosed
WO-2000050002-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-08-31 WO disclosed
WO-1997023202-A1 SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047296-A1 Low-Residue Cosmetic Or Dermatological Stick Based On An Oil-In-Water Dispersion/Emulsion III TYR, POLR1C, CUTA EGFR 1891/4885KDM4E 2435/4885MEN1 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.